

Patrys Limited

ABN 97 123 055 363

Annual Report - 30 June 2025

Corporate directory	2
Directors' report	3
Auditor's independence declaration	18
Statement of profit or loss and other comprehensive income	19
Statement of financial position	20
Statement of changes in equity	21
Statement of cash flows	22
Notes to the financial statements	23
Consolidated entity disclosure statement	44
Directors' declaration	45
Independent auditor's report to the members of Patrys Limited	46
Shareholder information	50

Directors	Mr. Peter Christie (Chair) Dr. James Campbell (Non-Executive Director) Dr. Anton Uvarov (Non-Executive Director)
Company secretary	Mr Stefan Ross
Registered office	Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 Ph: +61 3 9670 3273
Principal place of business	Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 Ph: +61 3 9670 3273
Share register	Computershare Investor Services Pty Limited 452 Johnston Street Abbotsford VIC 3067 Phone: 1300 850 505 (within Australia) Phone: +61 3 9415 4000 (outside Australia)
Auditor	BDO Audit Pty Ltd Tower 4, Level 18, 727 Collins Street Melbourne VIC 3008 Australia
Stock exchange listing	Patrys Limited shares are listed on the Australian Securities Exchange (ASX code: PAB)
Website	www.patrys.com

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Patrys Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2025.

Directors

The following persons were Directors of Patrys Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mr. Peter Christie (Chair - appointed on 17 June 2025)

Dr. James Campbell (Managing Director & CEO role made redundant, effective 1 July 2025, appointed as a Non-Executive Director on 1 July 2025)

Dr. Anton Uvarov (Non-Executive Director - appointed on 17 June 2025)

Dr. Charmaine Gittleson (Non-Executive Chair - resigned on 17 June 2025)

Dr. Pamela M. Klein (Non-Executive Director - resigned on 17 June 2025)

Mr. Michael Stork (Non-Executive Director and Deputy Chair - retired on 31 March 2025)

Principal activities

Patrys is using its proprietary deoxymab antibody technology platform to develop new therapies for the treatment of cancer and other diseases. Unlike most other antibodies, Patrys' deoxymabs are able to cross the blood-brain barrier, enter cells and the cell nucleus, and stop or significantly slow the growth of tumours with impaired DNA damage repair systems. Recently Patrys has shown that, by way of their DNA-binding properties, deoxymabs are able to inhibit a process called NETosis that is implicated in a number of inflammatory and autoimmune diseases including vasculitis.

Patrys has an exclusive, worldwide licence to the deoxymab technology for cancer applications from Yale University and is using this to develop and commercialise a portfolio of anti-cancer and diagnostic agents that include anti-DNA antibodies, antibody fragments, variants and conjugates. Patrys and Yale University also have filed intellectual property pertaining to the use of deoxymabs in a range of non-cancer indications, and Patrys holds the exclusive commercial rights for these opportunities.

At the start of the financial year Patrys was focused on advancing its lead agent PAT-DX1 towards a first in human clinical study. In the last quarter of FY2024, a large-scale production run of PAT-DX1 was completed in preparation for the clinical trial. In October 2024 the Company announced that specification testing of the drug material from this production run met the pre-determined thresholds, however for some parameters it only met those thresholds by a narrow margin. As a consequence, there was a significant risk that the drug material would not continue to meet specification for the time required to initiate and conduct a phase-1 clinical trial. In view of this, the Board of Patrys decided it was not appropriate to continue with plans to initiate a clinical trial of PAT-DX1 using this material. Given the challenges Patrys had previously experienced with manufacturing PAT-DX1 over several production runs, Patrys' Board made the decision to prioritise its future investment in development activities on progressing PAT-DX3.

For several years and in parallel, Patrys has been advancing the development of PAT-DX3 as an additional deoxymab asset. PAT-DX3 has shown very similar biological activity to PAT-DX1 including the ability to target tumours throughout the body and to cross the blood-brain barrier. As a full-sized IgG antibody, PAT-DX3 can also be used as the basis for Antibody Drug Conjugates. Patrys has completed the early stages of development for PAT-DX3 including clone selection, generation of Master Cell Bank (MCB) and development of upstream and downstream processes and formulation.

Following the decision to pivot to the development of PAT-DX3, Patrys worked with its research partners to evaluate and develop an R&D program to advance PAT-DX3 towards the clinic as a therapy for inflammatory diseases based on its ability to inhibit NETosis. At this stage it is believed that such a program may be feasible and that the associated clinical trials have the potential to require less drug material than for cancer indications due to the anticipated dosing regime and shorter time to achieve clinical endpoints. The Company has also initiated discussions with several third parties who are working on therapeutics based on the NETosis pathway.

As well as working on a funded development plan for PAT-DX3, the Company continues active programs to seek a partner for PAT-DX1, and continues to evaluate other assets that may enhance the Company's pipeline.

Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Review of operations

The loss for the Group after providing for income tax amounted to \$3,013,303 (30 June 2024: \$3,539,150).

R&D progress

Please refer the "Principal activities" section for the information and updates on R&D progress.

Corporate developments

In addition to exploring out-licensing opportunities of deoxymabs, the Company has been evaluating several additional assets that could diversify risk for shareholders. Several technologies and opportunities are currently being evaluated. However, as there is still a high degree of uncertainty regarding the outcome of this initiative, the Company will only be in a position to update shareholders of outcome of this process when it is further progressed.

As part of ongoing cost rationalisation, the Company is reviewing its license obligations to, and agreements with, Yale University across the deoxymab technology platform with a view to rationalising ongoing licenses such that they better align with any potential future development programs being pursued.

In June 2025 the Company undertook a restructure of its Board and management. Dr Gittleson (Non-Executive Chair) and Dr Klein (Non-Executive Director) stepped down from the Board on 17 June 2025, and were replaced by Mr Peter Christie (Non-Executive Chair) and Dr Anton Uvarov (Non-Executive Director). Dr Campbell accepted redundancy as CEO and Managing Director, and remains on the Board as a Non-Executive Director.

During June 2025 Patrys announced the successful completion of a \$308,362 capital raise by way of a placement of new shares and attaching options to sophisticated and professional investors. Funds raised will allow the Company to maintain its business development activities for the deoxymab program, providing financial leeway until the expected receipt of the Federal government's R&D rebate in the second half of 2025.

As a subsequent event, on 23 July 2025 the Company announced a fully underwritten non-renounceable Entitlement Offer to raise approximately \$1.774 million. The funds raised will provide working capital to fund ongoing evaluation of the potential of advancing PAT-DX3 to the clinic as well as business development costs (including the evaluation of new opportunities) as well as general operating and compliance costs and working capital.

Looking ahead

Patrys' operational efforts are threefold:

- Continue to build a robust package of non-clinical studies for deoxymabs, particularly in inflammation;
- Progress the ongoing partnering opportunities for both deoxymabs;
- Evaluate complementary assets that may enhance the Company's pipeline.

Statement of Financial Position

At 30 June 2025, the Group held cash of \$742,441 (30 June 2024: \$2,240,661). Excluding prepaid expenses, the working capital position at 30 June 2025 was \$561,514 (30 June 2024: \$2,893,697).

Operating results

The loss for the Group after providing for income tax amounted to \$3,013,303 (30 June 2024: \$3,539,150). Total other income during the year was \$828,540 (2024: \$1,394,163). This includes R&D tax incentive income of \$807,271 (2024: \$1,285,038).

Patrys' strategy is to outsource product development expenses, including manufacturing, regulatory and clinical trial expenses, to specialist, best of breed partner organisations. As a consequence, Patrys has not incurred any major capital expenditure for the year and does not intend to incur substantial commitments for capital expenditure in the immediate future.

Total consolidated operating expenses for the year were \$3,841,843 (2024: \$4,933,313). Operating expenses include research and development costs of \$1,754,163 (2024: \$3,071,793) which have been expensed in the year they were incurred. Level of R&D costs incurred in FY2025 is consistent with the pre-clinical and manufacturing works undertaken during the financial year. Administration and management costs contributed a further \$1,783,930 (2024: \$1,861,520) from continuing operations.

Risks and uncertainties

Patrys is subject to risks that are specific to the Group and its business activities, as well as general risks. Following are the significant risks and uncertainties relevant for current reporting year.

Future funding risks

The Group had a cash and cash equivalents balance of \$742,441, a receivable of \$807,271 in relation to the R&D tax incentives and net assets of \$732,874 at 30 June 2025.

The Company may require substantial further financing to finance the continue research, development and commercialisation of its technology / products and its other longer-term objectives.

Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations and scale back its research and development activities as the case may be. There is however no guarantee that the Company will be able to secure any additional funding or be able to secure funding on terms favourable to the Company.

Patrys' ability to raise additional funds will be subject to, among other things, factors beyond the control of the Company and its Directors, including cyclical factors affecting the economy and share markets generally. If for any reason Patrys was unable to raise future funds, its ability to achieve its milestones or continue future development / commercialisation of its assets would be significantly affected. The Directors regularly review the spending pattern and ability to raise additional funding to ensure Patrys' ability to generate sufficient cash inflows to settle its creditors and other liabilities. In addition, Patrys is eligible for certain government grants and R&D tax incentive payments.

Regulatory and licensing risks

Changes in relevant taxation, interest rates, other legal, legislative and administrative regimes and Government policies in Australia and in other markets in which the businesses of the Company do and will operate, may have an adverse effect on the assets, operations and ultimately the financial performance of the Company and the market price of its Securities.

The research, development, manufacture and sale of products based on Patrys' technology is subject to a number of regulations prescribed by government authorities in Australia and overseas. Generally, there is a high rate of failure for drug candidates proceeding through pre-clinical and clinical trials. Further, even if the Group views the results of a trial to be positive, the FDA or other regulatory authorities may disagree with the Group's interpretation of the data. Thus, any product based on Patrys' technology may be shown to be unsafe, non-efficacious, difficult or impossible to manufacture on a large scale, uneconomical to market, compete with superior products marketed by third parties, fail to secure meaningful reimbursement approval, or not be as attractive as alternative treatments. Patrys' monitors legislative and regulatory developments and engages proactively with key stakeholders to manage this risk.

Innovating technological development

Patrys' product range includes candidates that are in pre-clinical development and need to be further tested before they can progress to human clinical trials. Pre-clinical and clinical development of Patrys' product candidates could take several years to complete and might fail for a number of reasons including but not limited to lack of efficacy, failure to obtain regulatory approval, difficulty or failure to manufacture Patrys' products on a large scale, or toxicity. There is no guarantee that Patrys will be commercially successful.

Dependence on service providers and third-party collaborators

There is no guarantee that Patrys will be able to find suitable third-party providers and third-party collaborators including academic institutions to complete the development and commercialisation of its products. Patrys is therefore exposed to the risk that any of these parties can experience problems related to operations, financial strength or other issues, and collaborative agreements may be terminable by Patrys' partners. Non-performance, suspension or termination of relevant agreements could negatively impact the progress or success of Patrys' product development efforts, financial condition and results of operations.

Patrys monitors commercial developments and engages proactively with key stakeholders to manage this risk.

Reliance on key personnel

Patrys' success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including those employed on a contractual basis. The loss of the services of such personnel or the reduced ability to recruit additional personnel could have an adverse effect on the performance of Patrys. Patrys maintains a mixture of permanent staff and expert consultants to advance its programs and ensure access to multiple skill sets. Patrys, through the Remuneration and Nomination Committee reviews remunerations to human resources regularly.

Inability to protect intellectual property

Patrys' ability to leverage its innovation and expertise is dependent on its ability to protect its intellectual property including maintaining patent protection for its product candidates and their respective targets and any improvements to it. A failure or inability to protect Patrys' intellectual property rights could have an adverse impact on operating and financial performance.

Patrys owns or has in-licensed issued and pending patent applications covering a range of antibodies, cell lines, molecular targets, potential drug candidates and platform technologies. The prospect of attaining patent protection for products such as those Patrys proposes to develop is highly uncertain and involves complex and continually evolving factual and legal questions. Patrys may incur significant costs in prosecuting or defending its intellectual property rights.

Patrys proactively monitors applications and renewals of patents and licences; and requires relevant stakeholders to comply with the requirements set out in the confidentiality policy.

IT system failure and cyber security risks

Any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet and data network failures, and natural disasters.

Patrys is committed to preventing and reducing cyber security risks through outsourcing the IT management to a reputable services provider. In addition, Patrys has an insurance policy covering IT and cyber security matters.

Significant changes in the state of affairs

On 31 March 2025 the Company announced the retirement of Mr. Michael Stork as a Non-Executive Director.

On 10 June 2025, the Company announced the receipt of commitments for a capital raising of up to approximately \$308,362 before costs, by way of a placement of new shares at an issue price of \$0.01 per new share.

On 10 June 2025, the Company announced the appointment of Dr Anton Uvarov as a non-executive director and Mr Peter Christie as Chair, effective from 17 June 2025. On the same day, Dr Charmaine Gittleson and Dr Pamela M Klein have resigned as directors of the Company.

On 10 June 2025, the Company announced that the CEO and Managing Director, Dr James Campbell would accept redundancy as part of the rationalisation of the Company's cost base, with effect on 1 July 2025, and transition to a non-executive director from 1 July 2025.

There were no other significant changes in the state of affairs of the Group during the financial year.

Matters subsequent to the end of the financial year

As announced on 8 July 2025, 27,360,500 Options expired during the June 2025 quarter and on 1 July 2025, because the conditions have not been, or have become incapable of being, satisfied.

On 23 July 2025, the Company announced a fully underwritten non-renounceable Entitlement Offer to raise approximately \$1,774,357. On 27 August 2025 the Company advised that it has received applications under the Offer from eligible shareholders amounting to 423,479,439 Shares raising gross proceeds of \$423,479. On 28 August 2025, the Company issued a total of 529,349,257 shares, being the 423,479,439 shares applied for and accepted by eligible shareholders under the Offer, plus 105,869,818 free attaching shares. On 4 September 2025, the Company issued a total of 1,688,597,451 fully paid ordinary shares comprising of 1,350,877,963 shortfall Shares and 337,719,488 shortfall free attaching Shares raising \$1,350,878 from the Underwriter (and sub-underwriters).

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Likely developments and expected results of operations

The Group will continue to pursue its objective of developing antibodies as therapies for a range of different cancers and inflammatory diseases. Patrys has a pipeline of antibodies for both internal development and as partnering opportunities.

The Group's focus for the coming period will be to build further value into the Deoxymab platform through pre-clinical activities, and the planned progression of the PAT-DX1 and DX3 asset towards the clinic.

Environmental regulation

The Group is not subject to any significant environmental regulation under Australian Commonwealth or State law.

Information on Directors

Name: Peter Christie
Title: Non-Executive Chair (appointed on 17 June 2025)
Experience and expertise: Mr. Peter Christie is a qualified accountant and tax agent with over 25 years of experience in public accounting. He has served on the boards of several public companies in the resource sector since 2006 and has developed extensive interests in hospitality and property development.

Mr. Christie is the Director of Hawkins Christie Management Services, a firm based in Nedlands, Western Australia, providing accounting and management services. He is also the current President of the South Fremantle Football Club, a role he has held since 2018, following over a decade of service on the club's board. His leadership has been instrumental in the club's strategic growth and community engagement initiatives.

In addition to his roles in the resource sector and community sports, Mr. Christie has experience in the medical industry, having previously served as Chairman of Safety Medical Products Limited. His diverse background in finance, corporate governance, and community leadership positions him as a valuable asset to the board.

Other current directorships: None.
Former directorships (last 3 years): None.
Special responsibilities: Chair of the Nomination and Remuneration Committee (effective 26 August 2025)
 Member of the Audit and Risk Committee (effective 26 August 2025)
Interests in shares: 31,250,000 fully paid ordinary shares
Interests in options: None

Name: James Campbell
Title: Non-Executive Director (effective from 1 July 2025) formerly Managing Director and Chief Executive Officer, with that role being made redundant, effective 1 July 2025
Qualifications: Ph.D, MBA, GAICD
Experience and expertise: Dr. Campbell has over 30 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX: CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of \$10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for \$230M. Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. Dr Campbell chairs the board of AusBiotech Australia's peak industry body for biotechnology.

Other current directorships: Non-Executive Chair of Prescient Therapeutics Limited (ASX: PTX)
Former directorships (last 3 years): None.
Special responsibilities: Member of the Nomination and Remuneration Committee (effective 26 August 2025)
 Member of the Audit and Risk Committee (effective 26 August 2025)
Interests in shares: 36,589,928 fully paid ordinary shares
Interests in options: 23,389,950 unlisted options, exercisable at \$0.059, expiring on 30 September 2025.

Name:	Dr. Anton Uvarov
Title:	Non-Executive Director (appointed on 17 June 2025)
Experience and expertise:	Dr. Anton Uvarov brings extensive experience in the healthcare sector, with a particular focus on neuroscience. He began his career in biotechnology investment as an equities analyst at Citigroup and has since co-founded and served as a director of several ASX-listed companies, including clinical-stage ventures such as Dimerix (ASX:DXB) and Actinogen Medical (ASX:ACW). Dr. Uvarov is currently a Non-Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), and previously served on the board of Imugene (ASX:IMU), a late-stage clinical oncology company. Dr Uvarov is also the Executive Director and co-founder of BlinkLab (ASX:BB1), a digital diagnostics company focused on autism.
Other current directorships:	Non-Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), Executive Director of BlinkLab Limited (ASX:BB1).
Former directorships (last 3 years):	None.
Special responsibilities:	Chair of the Audit and Risk Committee (effective 26 August 2025) Member of the Nomination and Remuneration Committee (effective 26 August 2025)
Interests in shares:	250,000,000 fully paid ordinary shares
Interests in options:	None
Name:	Charmaine Gittleson (resigned on 17 June 2025)
Title:	Non-Executive Chair
Qualifications:	MD, BSci, AICD
Experience and expertise:	Dr Gittleson was the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in Australia and the USA. Dr Gittleson's expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management. Dr Gittleson has been involved in drug development programs across a wide range of different therapeutic areas, and has successfully worked with regulators in key markets such as the US, EU, Asia Pacific, Japan and South America. Dr Gittleson is currently the Chair of Percheron Therapeutics Limited (ASX: PER) where she has been actively involved in strategy development, capital raising and Board renewal.
Other current directorships:	Percheron Therapeutics (ASX:PER)
Former directorships (last 3 years):	None.
Special responsibilities:	Chair of Nomination and Remuneration Committee (ceased on 17 June 2025) Member of Audit and Risk Committee (ceased on 17 June 2025)
Interests in shares:	Nil
Interests in options:	2,000,000 unlisted options, exercisable at \$0.045 (4.5 cents), expiring 14 November 2026
Name:	Dr. Pamela M. Klein (resigned on 17 June 2025)
Title:	Non-Executive Director
Experience and expertise:	Dr. Klein has a proven track record as an executive over more than 20 years in the oncology and biopharmaceutical industry. She is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in severe autoimmune disease. She is also on the Board of Frontier Medicines; Shasqi and ONA Therapeutics. She was previously on the Board of Directors of F-Star Therapeutics, Jiya Acquisition Corp, a special purpose acquisition company (SPAC) affiliated with Samsara BioCapital, Sardona and I-MAB. Dr. Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development.
Other current directorships:	Argenx (arGEN-X ADS (NASD)), Argenx (arGENX (EURONEXT)), Frontier Medicines, ONA Therapeutics, Shasqi.
Former directorships (last 3 years):	F-star Therapeutics (NASDAQ: FSTX), I-MAB, Sardona, Jiya Acquisition Corp.
Special responsibilities:	Member of Nomination and Remuneration Committee (ceased on 17 June 2025) Member of Audit and Risk Committee (ceased on 17 June 2025)
Interests in shares:	250,000 fully paid ordinary shares.
Interests in options:	None.

Name:	Michael Stork (retired on 31 March 2025)
Title:	Non-Executive Director and Deputy Chair
Qualifications:	BBA
Experience and expertise:	Mr. Stork was the Managing Director of Stork Holdings Ltd, an Investment Holding company active in the Canadian technology start-up sector. Mr. Stork was on the Board of Governors of the University of Waterloo.
Other current directorships:	None.
Former directorships (last 3 years):	None.
Special responsibilities:	Member of Nomination and Remuneration Committee (ceased on 31 March 2025) Chair of Audit and Risk Committee (ceased on 31 March 2025)
Interests in shares:	98,773,814 fully paid ordinary shares (These shares are held by Stork Holdings Ltd. The director has the ability to influence the voting and disposal of the shares of this company).
Interests in options:	None.

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Company Secretary

Mr Stefan Ross BBus (Acc)

Mr Ross has over 12 years of experience in accounting and secretarial services for ASX listed companies. His extensive experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support. Mr Ross has a Bachelor of Business majoring in accounting.

Meetings of Directors

The number of meetings of the Company's Board of Directors ('the Board') and of each Board committee held during the year ended 30 June 2025, and the number of meetings attended by each Director were:

	Full Board		Nomination and Remuneration Committee		Audit and Risk Committee	
	Attended	Held	Attended	Held	Attended	Held
Charmaine Gittleson	10	11	1	1	2	2
James Campbell	11	11	-	-	-	-
Michael Stork	4	5	-	-	1	2
Pamela Klein	11	11	1	1	2	2

Held: represents the number of meetings held during the time the Director held office or was a member of the relevant committee.

Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Group, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including all directors.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

Principles used to determine the nature and amount of remuneration

The objective of the Group's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board ensures that executive reward satisfies the following key criteria for good reward governance practices:

- competitiveness and reasonableness;
- acceptability to shareholders;
- performance linkage / alignment of executive compensation;
- transparency; and
- risk and capital management.

The Board is responsible for determining and reviewing compensation arrangements for the Directors themselves, the Non-Executive Chair and the Senior Management team. The Board has established a Nomination and Remuneration Committee, comprising of three Directors, the majority of which are Non-Executive Directors. This Committee is primarily responsible for making recommendations to the Board on:

- the over-arching executive remuneration framework;
- the operation of the incentive plans, including key performance indicators and performance hurdles;
- remuneration levels of Executive Directors and other key management personnel; and
- Non-Executive Director fees.

The objective of this Committee is to ensure that remuneration policies and structures are fair and competitive and aligned with the long-term interests of the Company. The Corporate Governance Statement provides further information on the role of this committee and is available on the Company's website at www.patrys.com/patrys-corporate-governance.

The Group has structured an executive remuneration framework that is market competitive and complimentary to the reward strategy of the organisation.

The Group's remuneration framework seeks alignment with shareholders' interests and is in particular aligned to the rapid commercialisation of its intellectual property and in achieving its milestones in a highly ethical and professional manner.

The executive remuneration framework provides a mix of fixed and variable pay and performance incentive rewards. Presently, the Company's policy in relation to performance incentive rewards is to issue a mix of equity and cash bonuses to executives. The Company does not have a policy or practice of cancelling or clawing-back performance-based remuneration of its executives other than in accordance with the relevant plan rules.

In accordance with best practice corporate governance, the structure of Non-Executive Director and Executive Director remuneration is separate.

Non-executive Directors remuneration

Directors' fees are determined by reference to industry standards. Components of the remuneration package include a cash element together with equity instruments.

Directors' fees for the 2024/2025 financial year were set at \$95,000 for the Chair and \$60,000 per Non-Executive Director. Following the restructuring of the Board in June 2025, director fees are revised as \$75,000 for the Chair and \$48,000 per Non-Executive Director and reflect the demands which are made on and the responsibilities of the Directors. Mr. Michael Stork, one of the Non-Executive Director who resigned during the year did not receive any monetary fees during the year (2024: Nil).

ASX listing rules require the aggregate Non-Executive Directors' remuneration be determined periodically by a general meeting. The most recent determination was at the Annual General Meeting held on 22 November 2018, where the shareholders approved a maximum annual aggregate remuneration of \$400,000.

Executive remuneration

The Group aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits;
- short-term performance incentives;
- share-based payments; and
- other remuneration such as superannuation and long service leave.

The combination of these comprise the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, is reviewed annually by the Nomination and Remuneration Committee based on individual and business unit performance, the overall performance of the Group and comparable market remunerations.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the Group and provides additional value to the executive.

Incentives are payable to executives based upon the attainment of agreed corporate and individual milestones and are reviewed and approved by the Board.

Executives and Directors are issued with equity instruments as LTIs (Long Term Incentives) in a manner that aligns this element of remuneration with the creation of shareholder wealth. LTI grants are made to executives and Directors who are able to influence the generation of shareholder wealth and thus have a direct impact on the creation of shareholder wealth.

Group performance and link to remuneration

Equity instruments may be issued to new employees, and upon performance review based on performance of the individual and the Company both in absolute terms and relative to competitors in the biotechnology sector. Equity instruments that are issued for performance are subject to performance targets set and approved by the Nomination and Remuneration Committee.

Patrys' remuneration policy seeks to reward staff members for their contribution to achieving significant operational, strategic, partnering, preclinical, clinical and regulatory milestones. These milestones build sustainable and long-term shareholder value.

Voting and comments made at the Company's 22 November 2024 Annual General Meeting ('AGM')

At the 22 November 2024 AGM, 69.67% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2024. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

Details of remuneration

Board renewal and management restructure

The Company renewed the composition of the Board and management during June 2025. Dr Anton Uvarov and Mr Peter Christie were appointed as non-executive directors and Dr Charmaine Gittleson and Dr Pamela M Klein stepped down as directors of the Company, effective 17 June 2025. In addition, and as part of the Company's management review, the position of Chief Executive Officer was made redundant, effective 1 July 2025, and James Campbell remains on the Board of the Company as a non-executive director.

The Key Management Personnel of the Group consisted of the following directors of Patrys Limited:

- Mr. Peter Christie (Chair - appointed on 17 June 2025)
- Dr. James Campbell (appointed as non-executive director on 1 July 2025 and formerly the Managing Director and Chief Executive Officer with the role being made redundant, effective 1 July 2025)
- Dr. Anton Uvarov (Non-Executive Director - appointed on 17 June 2025)
- Dr. Charmaine Gittleson (Non-Executive Chair - resigned on 17 June 2025)
- Dr. Pamela Klein (Non-Executive Director - resigned on 17 June 2025)
- Mr. Michael Stork (Non-Executive Director and Deputy Chair retired on 31 March 2025)

	Short-term benefits	Post-employment benefits	Long-term benefits	Termination benefits	Total
	Salary and fees	Annual leave	Super-annuation	Long service leave	
30 June 2025	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>					
Peter Christie	2,790	-	335	-	3,125
Anton Uvarov	1,786	-	214	-	2,000
Charmaine Gittleson*	82,902	-	9,534	-	92,436
Pamela Klein*	89,490	-	-	-	89,490
<i>Executive Directors:</i>					
James Campbell**	371,279	13,199	24,963	7,319	878,206
	548,247	13,199	35,046	7,319	1,065,257

* Ms. Klein was paid USD 57,857 at an exchange rate of 0.64652 USD to 1 AUD. Ms Gittleson has retired and Ms Klein resigned effective 17 June 2025.

** Dr. James Campbell's role as Managing Director & CEO was made redundant, effective 1 July 2025 and was appointed as a Non-Executive Director on the same date. The disclosures above reflect his remuneration during his tenure as Executive Director and associated payments.

	Short-term benefits	Post-employment benefits	Long-term benefits	Share-based payments	Total
	Salary and fees	Annual leave	Super-annuation	Long service leave	
30 June 2024	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>					
Charmaine Gittleson	85,973	-	9,457	11,513	106,943
Suzy Jones*	18,758	-	-	-	18,758
Pamela Klein**	91,425	-	-	-	91,425
<i>Executive Directors:</i>					
James Campbell	372,649	25,462	27,500	43,397	487,074
	568,805	25,462	36,957	54,910	704,200

* Ms Jones was paid USD 15,000 at an exchange rate of 0.6625 USD to 1 AUD. Ms Jones retired on 15/9/2023.

** Ms Klein was paid USD 60,000 at an exchange rate of 0.6565 USD to 1 AUD.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

	Fixed remuneration		At risk - LTI	
Name	30 June 2025	30 June 2024	30 June 2025	30 June 2024
<i>Non-Executive Directors:</i>				
Peter Christie	100%	-	-	-
Anton Uvarov	100%	-	-	-
Charmaine Gittleson**	100%	89%	-	11%
Suzy Jones*	-	100%	-	-
Pamela Klein**	100%	100%	-	-
<i>Executive Directors:</i>				
James Campbell	100%	91%	-	9%

* Retired on 15 September 2023.

** Resigned on 17 June 2025

Service agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Mr. Peter Christie
Title:	Non-Executive Director and Chair
Agreement commenced:	17 June 2025
Term of agreement:	No fixed term.
Details:	\$75,000 per annum (including statutory superannuation), to be reviewed independently and annually by the Board.
Name:	Dr Anton Uvarov
Title:	Non-Executive Director
Agreement commenced:	17 June 2025
Term of agreement:	No fixed term.
Details:	\$48,000 per annum (including statutory superannuation), to be reviewed independently and annually by the Board.
Name:	Dr James Campbell
Title:	Non-Executive Director (appointed as a Non-Executive Director on 1 July 2025 and formerly Managing Director and Chief Executive Officer with that role being made redundant, effective 1 July 2025)
Agreement commenced:	13 April 2015 (Managing Director and Chief Executive Officer) and 1 July 2025 (Non-Executive Director)
Term of agreement:	<i>Managing Director and Chief Executive Officer</i> No fixed term for an ongoing term subject to termination by Patrys with 6 months' notice and termination by the employee with 6 months' notice of the employee to Patrys, or 12 months' notice in the event of a successful takeover. <i>Non-Executive Director</i> No fixed term.
Details:	<i>Non-Executive Director</i> \$48,000 per annum (including statutory superannuation), to be reviewed independently and annually by the Board. <i>Managing Director and Chief Executive Officer</i> Dr Campbell will be entitled to an annual salary (inclusive of superannuation) of \$416,555 effective 1 July 2024. The Remuneration Package is inclusive of any fringe benefits tax for which Patrys is liable in respect of the employee's total remuneration and any superannuation contributions. The employee's performance will be reviewed annually or more frequently if required.
Name:	Dr Pamela Klein (<i>resigned on 17 June 2025</i>)
Title:	Non- Executive Director
Agreement commenced:	1 October 2019
Term of agreement:	No fixed term.
Details:	USD 60,000 until resignation date.
Name:	Dr Charmaine Gittleson (<i>resigned on 17 June 2025</i>)
Title:	Non-Executive Chair
Agreement commenced:	16 November 2022
Term of agreement:	No fixed term
Details:	\$95,430 until resignation date.
Name:	Michael Stork (<i>retired on 31 March 2025</i>)
Title:	Non- Executive Director
Agreement commenced:	19 February 2007
Term of agreement:	No fixed term.
Details:	None.

Key Management Personnel have no entitlement to termination payments in the event of removal for misconduct.

Share-based compensation

Issue of shares

There were no shares issued to Directors and other Key Management Personnel as part of compensation during the year ended 30 June 2025.

Options

The terms and conditions of each grant of options over ordinary shares affecting remuneration of Directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
James Campbell	12,500,000	05/11/2021	05/11/2022 (i)	30/09/2025	\$0.0590	\$0.01840
James Campbell	12,500,000	05/11/2021	05/11/2023 (ii)	30/09/2025	\$0.0590	\$0.01980
Charmaine Gittleson	2,000,000	16/11/2022	16/11/2025 (iii)	14/11/2025	\$0.0450	\$0.00620

- (i) The share price is equal to or greater than a 20-day VWAP of \$0.07 (7.0 cents); exercisable thereafter. These options are not vested at the reporting date.
- (ii) Vest on or after the 24-month anniversary of grant date *and* the share price is equal to or greater than a 20-day VWAP of \$0.10 (10 cents). These options are not vested at the reporting date.
- (iii) 2,000,000 unlisted options vest on or after the 36-month anniversary of grant date and the share price is equal to or greater than a 20-day VWAP of 7.0 cents. These options are not vested at the reporting date.

Options granted carry no dividend or voting rights.

Details of options over ordinary shares lapsed for Directors and other Key Management Personnel, during the year ended 30 June 2025 are set out below:

Name	Grant date	Vesting date	Number of options lapsed	Value of options lapsed \$
James Campbell	05/11/2021	05/11/2022	5,500,000	68,475
James Campbell	05/11/2021	05/11/2022	5,500,000	74,525
Charmaine Gittleson	16/11/2022	16/11/2023	2,000,000	7,000
Charmaine Gittleson	16/11/2022	16/11/2024	2,000,000	9,400
Charmaine Gittleson	16/11/2022	16/11/2025	2,000,000	12,400

Amounts represent the fair value of Options previously recognised over the vesting period under AASB2 Share Based Payments. The fair value was determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted.

Additional information

The earnings of the Group for the five years to 30 June 2025 are summarised below:

	2025 \$	2024 \$	2023 \$	2022 \$	2021 \$
Other income	828,540	1,394,163	2,851,908	3,333,576	1,338,377
Loss before tax	(3,013,303)	(3,539,150)	(7,061,624)	(6,780,363)	(4,062,920)
Loss after tax	(3,013,303)	(3,539,150)	(7,061,624)	(6,780,363)	(4,062,920)

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	2025	2024	2023	2022	2021
Share price at financial year start (\$)	0.0070	0.0100	0.0200	0.0560	0.0120
Share price at financial year end (\$)	0.0010	0.0070	0.0100	0.0200	0.0560
Basic losses per share (cents per share)	(0.1458)	(0.1722)	(0.3436)	(0.3458)	(0.2524)

Additional disclosures relating to key management personnel

Shareholding

The number of shares in the Company held during the financial year by each Director and other members of Key Management Personnel of the Group, including their related parties, is set out below:

	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
<i>Ordinary shares</i>					
James Campbell	18,885,125	-	-	-	18,885,125
Michael Stork*	98,773,814	-	-	(98,773,814)	-
Pamela Klein**	250,000	-	-	(250,000)	-
	<u>117,908,939</u>	<u>-</u>	<u>-</u>	<u>(99,023,814)</u>	<u>18,885,125</u>

* Mr. Michael Stork retired on 31 March 2025.

** Dr. Pamela M. Klein resigned on 17 June 2025.

Option holding

The number of options over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

	Balance at the start of the year	Granted	Exercised	Expired/ other	Balance at the end of the year
<i>Options over ordinary shares</i>					
James Campbell*	36,000,000	-	-	(11,000,000)	25,000,000
Michael Stork**	800,000	-	-	(800,000)	-
Pamela Klein***	4,800,000	-	-	(4,800,000)	-
Charmaine Gittleson***	8,000,000	-	-	(6,000,000)	2,000,000
	<u>49,600,000</u>	<u>-</u>	<u>-</u>	<u>(22,600,000)</u>	<u>27,000,000</u>

* 11,000,000 unlisted options lapsed on 24 December 2024.

** Mr. Micheal Stork retired as a director on 31 March 2025.

*** Dr. Charmaine Gittleson and Dr. Pamela Klein stepped down as Directors on 17 June 2025. Dr. Gittleson retained 2,000,000 unlisted options in accordance with the terms and conditions of the Options and the Company's Equity Incentive Plan Rules. The remainder of the unlisted options which had not vested, lapse immediately at cessation of Directorship.

This concludes the remuneration report, which has been audited.

Shares under option

Unissued ordinary shares of Patrys Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
5 November 2021 to 19 November 2021	30 September 2025	\$0.0590	32,889,950
19 November 2021	15 March 2026	\$0.0590	2,500,000
16 November 2022	16 November 2026	\$0.0450	2,000,000
15 March 2023	30 September 2026	\$0.0450	500,000
			<u>37,889,950</u>

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

Indemnity and insurance of officers

The Company has indemnified the Directors and executives of the Company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the directors and executives of the Company against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Non-audit services

The Company may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Company and/or the Group are important.

Details of the amount paid or payable to the auditor (BDO Audit Pty Ltd) and its related entities for audit and non-audit services provided during the year are set out in note 18.

The Board of Directors has considered the position and, in accordance with the advice received from the Audit and Risk Committee, is satisfied that the provision of the non-audit services is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001* for the following reasons:

- All non-audit services have been reviewed by the Audit and Risk Committee to ensure they do not impact the impartiality and objectivity of the auditor.
- None of the services undermine the general principles relating to auditor independence as set out in Professional Statement APES 110, including reviewing or auditing the auditor's own work, acting in a management or a decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risk and rewards.

Officers of the Company who are former partners of BDO Audit Pty Ltd and its related entities

There are no officers of the Company who are former partners of BDO Audit Pty Ltd and its related entities.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this Directors' report.

Auditor

BDO Audit Pty Ltd continues in office in accordance with section 327 of the *Corporations Act 2001*.

Rounding of amounts

Patrys Limited is a type of Company that is referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191 and therefore the amounts contained in this report and in the financial report have been rounded to the nearest dollar.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

On behalf of the Directors



Peter Christie
Chair

5 September 2025



Tel: +61 3 9603 1700
Fax: +61 3 9602 3870
www.bdo.com.au

Collins Square, Tower Four
Level 18, 727 Collins Street
Melbourne VIC 3008
GPO Box 5099 Melbourne VIC 3001
Australia

DECLARATION OF INDEPENDENCE BY WAI AW TO THE DIRECTORS OF PATRYS LIMITED

As lead auditor of Patrys Limited for the year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Patrys Limited and the entities it controlled during the period.

A handwritten signature in black ink, appearing to read 'Wai Aw', is written over a horizontal line.

Wai Aw
Director

BDO Audit Pty Ltd

Melbourne, 5 September 2025

		Consolidated	
	Note	30 June 2025	30 June 2024
		\$	\$
Research and development tax incentive and other income	5	828,540	1,394,163
Expenses			
Research and development expenses	6	(1,754,163)	(3,071,793)
Administration and management expenses	6	(1,783,930)	(1,861,520)
Impairment of intangible assets	10	(303,750)	-
Loss before income tax expense		(3,013,303)	(3,539,150)
Income tax expense	7	-	-
Loss after income tax expense for the year attributable to the Owners of Patrys Limited		(3,013,303)	(3,539,150)
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year attributable to the Owners of Patrys Limited		<u>(3,013,303)</u>	<u>(3,539,150)</u>
		Cents	Cents
Basic losses per share	25	(0.1458)	(0.1722)
Diluted losses per share	25	(0.1458)	(0.1722)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

		Consolidated	
	Note	30 June 2025	30 June 2024
		\$	\$
Assets			
Current assets			
Cash and cash equivalents	8	742,441	2,240,661
Trade and other receivables	9	825,283	1,341,771
Prepayments		171,360	226,097
Total current assets		<u>1,739,084</u>	<u>3,808,529</u>
Non-current assets			
Equipment		-	4,301
Intangibles	10	-	348,750
Total non-current assets		<u>-</u>	<u>353,051</u>
Total assets		<u>1,739,084</u>	<u>4,161,580</u>
Liabilities			
Current liabilities			
Trade and other payables	11	928,502	371,117
Employee benefits	12	77,708	317,618
Total current liabilities		<u>1,006,210</u>	<u>688,735</u>
Non-current liabilities			
Employee benefits	12	-	2,630
Total non-current liabilities		<u>-</u>	<u>2,630</u>
Total liabilities		<u>1,006,210</u>	<u>691,365</u>
Net assets		<u>732,874</u>	<u>3,470,215</u>
Equity			
Issued capital	13	86,010,399	85,734,437
Reserves	14	925,475	1,610,027
Accumulated losses		(86,203,000)	(83,874,249)
Total equity		<u>732,874</u>	<u>3,470,215</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2023	85,730,143	2,226,876	(81,119,441)	6,837,578
Loss after income tax expense for the year	-	-	(3,539,150)	(3,539,150)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(3,539,150)	(3,539,150)
<i>Transactions with owners in their capacity as owners:</i>				
Contributions of equity, net of transaction costs (note 13)	4,294	-	-	4,294
Reallocation of value of expired and cancelled options	-	(784,342)	784,342	-
Share based payments (note 6)	-	163,291	-	163,291
Transfer of foreign currency reserve on deregistration of the subsidiary	-	4,202	-	4,202
Balance at 30 June 2024	<u>85,734,437</u>	<u>1,610,027</u>	<u>(83,874,249)</u>	<u>3,470,215</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2024	85,734,437	1,610,027	(83,874,249)	3,470,215
Loss after income tax expense for the year	-	-	(3,013,303)	(3,013,303)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(3,013,303)	(3,013,303)
<i>Transactions with owners in their capacity as owners:</i>				
Share issue	308,363	-	-	308,363
Share issue costs (note 13)	(32,401)	-	-	(32,401)
Reallocation of value of expired and cancelled options	-	(684,552)	684,552	-
Balance at 30 June 2025	<u>86,010,399</u>	<u>925,475</u>	<u>(86,203,000)</u>	<u>732,874</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

		Consolidated	
	Note	30 June 2025	30 June 2024
		\$	\$
Cash flows from operating activities			
Payments to suppliers and employees (inclusive of GST)		(3,081,020)	(4,650,629)
Receipts from interest income		21,800	103,088
Receipts from R&D tax incentive		1,285,038	2,731,604
Net cash used in operating activities	24	(1,774,182)	(1,815,937)
Cash flows from investing activities			
Payments for equipment		-	(3,236)
Proceeds from investments in term deposits		-	1,010,024
Net cash from investing activities		-	1,006,788
Cash flows from financing activities			
Proceeds from issue of shares	13	308,363	4,294
Share issue transaction costs		(32,401)	-
Net cash from financing activities		275,962	4,294
Net decrease in cash and cash equivalents		(1,498,220)	(804,855)
Cash and cash equivalents at the beginning of the financial year		2,240,661	3,045,516
Cash and cash equivalents at the end of the financial year	8	742,441	2,240,661

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Patrys Limited as a Group consisting of Patrys Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Patrys Limited's functional and presentation currency.

Patrys Limited is a listed public company limited by shares, incorporated and domiciled in Australia.

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 5 September 2025. The Directors have the power to amend and reissue the financial statements.

Note 2. Material accounting policy information

The accounting policies that are material to the Group are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

Basis of preparation

These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. These financial statements also comply with IFRS accounting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Comparative figures

Where necessary, comparative information has been reclassified and repositioned for consistency with current year disclosures.

Going concern

For the year ended 30 June 2025, the Group incurred a loss after income tax of \$3,013,303 (30 June 2024: \$3,539,150) and had consolidated net operating cash outflows of \$1,774,182 (30 June 2024: \$1,815,937). As at 30 June 2025, the cash balance was \$742,441 (30 June 2024: \$2,240,661) and net asset position was \$732,874 (30 June 2024: \$3,470,215).

As a result of these matters there is a material uncertainty that may cast significant doubt upon the Group's ability to continue as a going concern and therefore whether the Group will realise its assets and settle its liabilities in the ordinary course of business at the amounts recorded in the financial statements.

The continuing viability of the Group and its ability to continue as a going concern is dependent upon the Group being successful in its continuing efforts in R&D activities, potential licensing of existing products and accessing additional sources of capital to meet future commitments. The existence of these conditions give rise to a material uncertainty that may cast significant doubt on the ability of the Group to continue as a going concern.

Notwithstanding the above, the Directors determined that the use of the going concern basis of accounting is appropriate in preparing the financial statements. The assessment of the going concern assumption is based on the Group's cash flow projections and application of a number of judgements and estimates. These includes the following features:

Note 2. Material accounting policy information (continued)

- On 23 July 2025, the Company announced a fully underwritten non-renounceable Entitlement Offer to raise approximately \$1,774,357. On 27 August 2025 the Company advised that it has received applications under the Offer from eligible shareholders amounting to 423,479,439 Shares raising gross proceeds of \$423,479. On 28 August 2025, the Company issued a total of 529,349,257 shares, being the 423,479,439 shares applied for and accepted by eligible shareholders under the Offer, plus 105,869,818 free attaching shares.
- On 4 September 2025, the Company issued a total of 1,688,597,451 fully paid ordinary shares comprising of 1,350,877,963 shortfall Shares and 337,719,488 shortfall free attaching Shares raising \$1,350,878 from the Underwriter (and sub-underwriters). The funds raised will provide working capital to fund ongoing evaluation of the potential of advancing PAT-DX3 to the clinic as well as business development costs (including the evaluation of new opportunities) as well as general operating and compliance costs and working capital.
- At 30 June 2025, the Group recognised a receivable of \$807,271 from the R&D tax incentive, which is expected to be received in the first half of the 2026 financial year.
- As the Group is still in the R&D phase of activities it has the ability to control the level of its operations and hence the level of its expenditure over the next 12 months. Should there be any delay in R&D refunds, management are confident that they can defer their level of expenditure in order to retain appropriate cash balances.

The Directors will continue to monitor the ongoing funding requirements of the Group. As a consequence of the above, the directors believe that, notwithstanding the Group's operating results for the year, the Group will be able to continue as a going concern.

Should the Group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of the business, and at amounts that differ from those stated in the consolidated financial statements. The consolidated financial statements does not include any adjustments relating to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessarily incurred should the Group not continue as a going concern.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Parent entity information

In accordance with the *Corporations Act 2001*, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 21.

Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Patrys Limited ('Company' or 'parent entity') as at 30 June 2025 and the results of all subsidiaries for the year then ended. Patrys Limited and its subsidiaries together are referred to in these financial statements as the 'Group'.

Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Note 2. Material accounting policy information (continued)

Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

Foreign currency translation

The financial statements are presented in Australian dollars, which is Patrys Limited's functional and presentation currency.

Foreign currency transactions

Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Impairment of non-financial assets

As a part of the impairment assessment for June 2025, management reviewed changes to laws and regulations affecting the IP, technological obsolescence, issues with funding commitment, along with a host of other indicators such as market value review, adverse movements in market rates of return and change in use of asset or the manner in which it used. There are no indicators of impairment of the asset for the year ended 30 June 2025 as a result of this review.

R&D Tax Incentives

The Australian Government has provided a tax incentive, in the form of a refundable tax offset of 48.5% (2024: 48.5%), for eligible research and development expenditure. Management have assessed refundable R&D tax incentive based on the research and development activities and expenditure during the period, which are likely to be eligible under the scheme. Amounts received are subject to Group's continued eligibility to the scheme.

Note 4. Operating segments

Identification of reportable operating segments

A segment is a component of the Group that engages in business activities to provide products or services within a particular economic environment. The Group operates in one business segment, being the conduct of research and development activities in the biopharmaceutical sector. The Board of Directors assess the operating performance of the Group based on management reports that are prepared on this basis. The Group has established activities in more than one geographical area; however, these activities support the research and development conducted by the Group and are considered immaterial for the purposes of segment reporting. The Group invests excess funds in short-term deposits, but this is not regarded as a separate segment.

Accounting policy for operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the managing director who is the Chief Operating Decision Maker ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Note 5. Research and development tax incentive and other income

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
R&D tax incentive	807,271	1,285,038
Interest income	21,269	109,125
Total research and development tax incentive and other income	<u>828,540</u>	<u>1,394,163</u>

R&D tax incentive income

Research and Development tax incentives are recognised in accordance with AASB 120: Accounting for Government Grants and Disclosure of Government Assistance. The Research and development tax incentive is recognised when there is reasonable assurance that the grant will be received, and all conditions have been complied with.

Interest

Interest income is recognised over the relevant period using the effective interest rate method.

Note 6. Expenses

	Consolidated 30 June 2025	30 June 2024
	\$	\$
Loss before income tax includes the following specific expenses:		
<i>Depreciation</i>		
Equipment	4,301	1,997
<i>Amortisation</i>		
License and registered patents	45,000	45,000
Total depreciation and amortisation	49,301	46,997
<i>Operating expenses</i>		
Clinical development, consultancy and laboratory consumables	1,367,371	2,510,663
Employment expenses associated with research and development	386,791	561,131
Administration and management expenses	895,701	1,057,961
	2,649,863	4,129,755
<i>Net foreign exchange loss</i>		
Net foreign exchange (gains) / loss	(2,117)	12,407
<i>Employee salary and benefit expense</i>		
Defined contribution superannuation expense	66,264	81,231
Salary and employee benefit expenses (excluding employment expenses associated with research and development)	774,782	499,632
Total employment expenses	841,046	580,863
<i>Share based payments expense</i>		
Share based payments	-	163,291

Note 7. Income tax expense

	Consolidated 30 June 2025	30 June 2024
	\$	\$
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Loss before income tax expense	(3,013,303)	(3,539,150)
Tax at the statutory tax rate of 25%	(753,326)	(884,788)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Effect of revenue that is not assessable in determining taxable income	(204,577)	(321,260)
Effect of expenses that are not deductible in determining taxable income	416,599	706,923
Deferred tax assets not brought to account	541,304	499,125
Income tax expense	-	-

Note 7. Income tax expense (continued)

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Deferred tax assets not recognised</i>		
Deferred tax assets not recognised comprises:		
Tax losses - revenue	15,945,038	15,636,293
Deductible temporary differences	182,601	196,209
Total deferred tax assets not recognised	<u>16,127,639</u>	<u>15,832,502</u>

The benefit of these deferred tax assets (not recognised) will only be obtained if:

- (i) the entities derive future assessable income of a nature and of an amount sufficient to enable the benefits from the deduction for losses to be realised;
- (ii) the entities continue to comply with the conditions for deductibility imposed by the law;
- (iii) no changes in tax legislation adversely affect the entities in realising the relevant benefits from deduction for the losses.

Income tax

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

- When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or
- When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

Note 8. Cash and cash equivalents

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Current assets</i>		
Cash at bank	<u>742,441</u>	<u>2,240,661</u>

Note 8. Cash and cash equivalents (continued)

The Group's exposure to interest rate and foreign currency risk is discussed in note 16.

Accounting policy for cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Note 9. Trade and other receivables

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Current assets</i>		
Research and Development tax incentive receivable	807,271	1,285,038
Other receivables	18,012	56,733
	<u>825,283</u>	<u>1,341,771</u>

Allowance for expected credit losses

In relation to the trade and other receivables, the Group has recognised a loss of Nil (30 June 2024: Nil) in profit or loss in respect of the expected credit losses for the year ended 30 June 2025.

Accounting policy for other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 10. Intangibles

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Non-current assets</i>		
Intellectual property - at cost	720,000	720,000
Less: Accumulated amortisation	(416,250)	(371,250)
Less: Provisions for impairment	(303,750)	-
	<u>-</u>	<u>348,750</u>

Note 10. Intangibles (continued)

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Intellectual property \$
Balance at 1 July 2023	393,750
Amortisation expense	(45,000)
Balance at 30 June 2024	348,750
Amortisation expense	(45,000)
Impairment of assets	(303,750)
Balance at 30 June 2025	-

In 2016 the Group acquired Nucleus intellectual property. The acquisition provides Patrys with licence rights to a portfolio of novel anti-DNA antibodies that penetrate cell nuclei. This novel pre-clinical oncology asset and platform have multiple potential applications to treat a range of cancers and inflammatory diseases.

Intangible assets comprise licences, intellectual property, trademarks and registered patents and have a finite useful life. Amortisation has been historically calculated using straight line method over the estimated useful life, which ranges from 5 to 20 years. The Group amortises the Nucleus intellectual property based on an estimated useful life of 16 years.

Intellectual property which includes platform technology and product related intellectual property is reviewed on a regular basis and where a decision has been made not to pursue a product, the remaining value recorded as an asset is impaired. At each reporting date, the directors also review the intellectual property portfolio to determine whether there are any other indicators of impairment related to intellectual property.

As announced to the market on 2 October 2024, specification testing on the material from the GMP run of PAT-DX1 means that material is not suitable for Patrys to initiate a Phase 1 clinical trial. Currently, the Group is focused on PAT-DX3 development pathway and actively seeking partnering or licensing opportunities for PAT-DX1. Given the developments, the Board, recognised an impairment of the intangible assets at 30 June 2025. However, the Group will review this position based on the development of PAT-DX3 in the future reporting periods.

Note 11. Trade and other payables

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Current liabilities</i>		
Trade payables	135,989	238,390
Other creditors and accruals	792,513	132,727
	928,502	371,117

Refer to note 16 for further information on financial instruments.

Accounting policy for trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Note 12. Employee benefits

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Current liabilities</i>		
Annual leave	24,086	196,679
Long service leave	53,622	120,939
	<u>77,708</u>	<u>317,618</u>
<i>Non-current liabilities</i>		
Long service leave	-	2,630
	<u>-</u>	<u>2,630</u>

Accounting policy for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Note 13. Issued capital

	Consolidated			
	30 June 2025	30 June 2024	30 June 2025	30 June 2024
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>2,364,112,771</u>	<u>2,055,750,236</u>	<u>86,010,399</u>	<u>85,734,437</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2023	2,055,571,295		85,730,143
Issue of shares upon exercise of options	26 July 2023	148,940	\$0.0240	3,574
Issue of shares upon exercise of options	8 August 2023	30,001	\$0.0240	720
Balance	30 June 2024	2,055,750,236		85,734,437
Share issue	18 June 2025	308,362,535	\$0.0010	308,363
Share issue costs				(32,401)
Balance	30 June 2025	<u>2,364,112,771</u>		<u>86,010,399</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Capital risk management

The Group's objective when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the consolidated Statement of Financial Position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

Note 13. Issued capital (continued)

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares.

The Group would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current company's share price at the time of the investment.

The capital risk management policy remains unchanged from the 30 June 2024 Annual Report.

Accounting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Note 14. Reserves

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Share options reserve	745,475	1,430,027
Other reserves	180,000	180,000
	<u>925,475</u>	<u>1,610,027</u>

Share based payment reserve

The equity settled share-based payment reserves arise on issue of options under the Employee Share Based Payment plan to executives and senior employees. Amounts are transferred out of the reserves and into issued capital when the options are converted to shares. Amounts are transferred to accumulated losses when the shares or options are cancelled. Further information about share-based payments during the year is provided in note 26 of the financial statements.

Other reserves

The other reserve consists of Tranche 3 shares for the acquisition of Nucleus Intellectual Property. When the Group meets the relevant milestone and the shares are issued, the amount is transferred out of the reserve and into issued capital.

Note 15. Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 16. Financial instruments

Financial risk management objectives

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. There have been no changes to these risks since the previous financial year. The Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, foreign exchange, ageing analysis for credit risk and cashflow forecasts to determine liquidity risk.

The Board of Directors ensures that the Group maintains a competent management structure capable of defining, analysing, measuring and reporting on the effective control of risks inherent in the Group's underlying financial activities and the instruments used to manage risk. Key financial risks including interest rate risk and foreign currency risk are reviewed by management on a regular basis and are communicated to the Board so that it can evaluate and impose its oversight responsibility. The Group does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes. The Company and the Group have a policy regarding foreign exchange risk management. This and other financial risks are managed prudently by the Board.

Note 16. Financial instruments (continued)

Market risk

Foreign currency risk

The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the Group's functional currency. The risk is measured using cash flow forecasting and sensitivity analysis.

The Group purchase and maintained cash in US dollars, Pound Sterling and Euros to cover a portion of its anticipated US dollar and Euro expenditure commitments.

The Group undertakes certain transactions denominated in foreign currencies, hence exposures to exchange rate fluctuation arise. Exchange rate exposures are managed within approved policy parameters. The Group manages the currency risk by monitoring the trend of the US dollar, Pound Sterling and Euro. The Group maintains US dollar, Pound Sterling and Euro bank accounts to cover a portion of its recognised financial liabilities and future commercial transactions in the respective foreign currencies.

The carrying amount of the Group's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	Assets		Liabilities	
	30 June 2025	30 June 2024	30 June 2025	30 June 2024
Consolidated	\$	\$	\$	\$
US dollars	94,222	53,795	(5,661)	(161,748)
Euros	99,263	88,916	-	-
Pound Sterling	15,379	13,915	-	-
	<u>208,864</u>	<u>156,626</u>	<u>(5,661)</u>	<u>(161,748)</u>

AUD strengthened				AUD weakened		
Consolidated - 30 June 2025	% Change	Effect on loss after tax	Effect on equity after tax	% Change	Effect on loss after tax	Effect on equity after tax
US Dollars	10%	(9,080)	(9,080)	-	9,080	9,080
Euros	10%	(9,024)	(9,024)	-	9,024	9,024
Pound Sterling	10%	(1,398)	(1,398)	-	1,398	1,398
		<u>(19,502)</u>	<u>(19,502)</u>		<u>19,502</u>	<u>19,502</u>

AUD strengthened				AUD weakened		
Consolidated - 30 June 2024	% Change	Effect on loss after tax	Effect on equity after tax	% Change	Effect on loss after tax	Effect on equity after tax
US Dollars	10%	9,814	9,814	10%	(9,814)	(9,814)
Euros	10%	(8,083)	(8,083)	10%	8,083	8,083
Pound Sterling	10%	(1,265)	(1,265)	10%	1,265	1,265
		<u>466</u>	<u>466</u>		<u>(466)</u>	<u>(466)</u>

Price risk

Price risk is the risk that future cashflows derived from financial instruments will be changed as a result of a market price movement, other than foreign currency rates and interest rates. Group is not exposed to any material commodity price risks.

Note 16. Financial instruments (continued)

Interest rate risk

The Group's exposure to market interest rates relates primarily to the Group's short-term deposits held and deposits at call. The Group had no interest-bearing financial liabilities at the reporting date. The variance in market interest rates on interest income is not material.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. The Group has reviews the creditworthiness of the counterparties prior to engagement and obtaining sufficient collateral where appropriate as a means of mitigating the risk of financial loss from defaults. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Group does not hold any collateral at the reporting date.

Receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is not significant. There are no significant concentrations of credit risk within the Group and financial instruments are spread amongst a number of financial institutions to minimise the risk of default of counterparties. The credit risk on liquid funds and financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit rating agencies. The Group measures credit risk on a fair value basis.

The carrying value of financial assets recorded in the financial statements, net of any allowances for losses, represents the Group's maximum exposure to credit risk. Maturity analysis of financial assets and liabilities based on management's expectations as follows:

Liquidity risk

Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. The Group has no borrowings at reporting date and the Directors ensure that the cash on hand is sufficient to meet the commitments of the Group at all times during the research and development phase.

Operating cash flows are used to maintain and expand the Group's assets. The Group manages liquidity risk by monitoring forecast cash flows and ensuring that adequate cash and also through assessment of available funding to identify risks to the cash position of the business.

Remaining contractual maturities

The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the Statement of Financial Position.

Consolidated - 30 June 2025	1 year or less \$	Remaining contractual maturities \$
Non-derivatives		
<i>Non-interest bearing</i>		
Trade payables	135,989	135,989
Other payables	792,513	792,513
Total non-derivatives	928,502	928,502

Note 16. Financial instruments (continued)

	1 year or less \$	Remaining contractual maturities \$
Consolidated - 30 June 2024		
Non-derivatives		
<i>Non-interest bearing</i>		
Trade payables	238,390	238,390
Other payables	132,727	132,727
Total non-derivatives	371,117	371,117

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Note 17. Key management personnel disclosures

Directors

The following persons were Directors of Patrys Limited during the financial year:

Mr. Peter Christie (Chair - appointed on 17 June 2025)

Dr. James Campbell (Managing Director & CEO with that role being made redundant, effective 1 July 2025, and appointed as Non-Executive Director on 1 July 2025)

Dr. Anton Uvarov (Non-Executive Director - appointed on 17 June 2025)

Dr. Charmaine Gittleson (Non-Executive Chair - resigned on 17 June 2025)

Dr. Pamela M. Klein (Non-Executive Director - resigned on 17 June 2025)

Mr. Michael Stork (Non-Executive Director and Deputy Chair retired on 31 March 2025)

Compensation

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Short-term employee benefits	561,446	594,267
Post-employment benefits	35,046	36,957
Long-term benefits	7,319	18,066
Termination benefits	461,446	-
Share-based payments	-	54,910
	1,065,257	704,200

Note 18. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by the auditor and its related entities of the Company:

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
<i>Audit services - BDO Audit Pty Ltd</i>		
BDO Audit Pty Ltd - Audit or review of the financial statements	95,000	90,000
<i>Other services - BDO Services Pty Ltd</i>		
BDO Services Pty Ltd - Review and lodgement of corporate tax returns	22,000	18,500
	<u>117,000</u>	<u>108,500</u>

Note 19. Commitments and contingent liabilities

Capital expenditure commitments

There was no capital expenditure contracted for at reporting date but not provided for in the financial statements at 30 June 2025 (30 June 2024: None).

Licence agreements

Patrys has entered into a number of licence agreements in respect of technologies and assets as outlined below. There were no changes to the first two agreements from the 30 June 2024 Annual Report. The latter agreement (Payload Therapeutics) was terminated on 17 April 2025 as the Company was not developing and payload-associated uses that depended on the licenced technology.

Nucleus Therapeutics – Yale University – License, Commercialisation and Development Agreement

In March of 2016, Patrys acquired the Nucleus Therapeutics Pty Ltd, in order to obtain the global license for the development as anti-cancer agents the antibodies 3E10 and 5C6 from Yale University. Once developed, certain milestone payments and royalties will be payable to Yale University regarding products that derive from 3E10 and/or 5C6. These milestones and royalties are typical in the industry for transactions of this nature.

Nucleus Therapeutics – Sigma Aldrich Pty Ltd Non-Exclusive Licence Agreement

In February of 2021, Nucleus Therapeutics (a wholly-owned subsidiary of Patrys) entered into a licence agreement with Sigma Aldrich Pty Ltd., covering the use of Sigma's CHOZN GS cell line for Patrys' product, PAT-DX1. If Patrys wishes to commercialise any of the products developed under the licence agreement it has the right to enter into a commercial license with Sigma which would incur a marketing approval fee (AUD conversion to be completed at applicable future exchange rates) payable upon filing per marketing approval in the US, the EU and any other market. The marketing approval fee is typical in the industry for transactions of such nature.

Payload Therapeutics – Yale University – License, Commercialisation and Development Agreement

In June 2017, Payload Therapeutics (a wholly-owned subsidiary of Patrys) obtained the global license for the development as anti-cancer agents the antibodies 3E10 nanoparticles from Yale University. Once developed, certain milestone payments and royalties will be payable to Yale University regarding products that derive from 3E10 nanoparticles. These milestones and royalties are typical in the industry for transactions of this nature. This agreement was terminated by mutual consent on 17 April 2025.

Contingent liabilities

The Group does not have any contingent liabilities or assets at the reporting date.

Note 20. Related party transactions

Parent entity

Patrys Limited is the parent entity.

Subsidiaries

Interests in subsidiaries are set out in note 22.

Note 20. Related party transactions (continued)

Key management personnel

Disclosures relating to key management personnel are set out in note 17 and the remuneration report included in the Directors' report.

Transactions with related parties

There were no transactions with related parties during the current and previous financial year.

Receivable from and payable to related parties

There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties

Transactions with controlled entities

There were no loans to/from related parties at the current and previous reporting date.

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 21. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent	
	30 June 2025	30 June 2024
	\$	\$
Loss after income tax	<u>(2,606,269)</u>	<u>(1,464,700)</u>
Other comprehensive income for the year, net of tax	<u>-</u>	<u>-</u>
Total comprehensive income	<u>(2,606,269)</u>	<u>(1,464,700)</u>

Note 21. Parent entity information (continued)

Statement of financial position

	Parent	
	30 June 2025	30 June 2024
	\$	\$
Total current assets	789,706	2,289,890
Total non-current assets	-	353,051
Total assets	789,706	2,642,941
Total current liabilities	951,917	472,214
Total non-current liabilities	-	2,630
Total liabilities	951,917	474,844
Net (liabilities) / assets	(162,211)	2,168,097
Equity		
Issued capital	86,010,399	85,734,437
Share options reserve	925,475	1,610,027
Accumulated losses	(87,098,085)	(85,176,367)
Total equity / (deficiency)	(162,211)	2,168,097

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The Company had no guarantees in relation to the debts of its subsidiaries as at 30 June 2025 (2024: Nil).

Contingent liabilities

The parent entity had no contingent liabilities as at 30 June 2025 (2024: Nil).

Capital commitments - Property, plant and equipment

The parent entity had no capital commitments for property, plant and equipment as at 30 June 2025 (2024: Nil).

Material accounting policy information

The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 2, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.

Note 22. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

Name	Principal place of business / Country of incorporation	Ownership interest	
		30 June 2025	30 June 2024
		%	%
Nucleus Therapeutics Pty Ltd	Australia	100%	100%
Payload Therapeutics Pty Ltd	Australia	100%	100%
Transmab Pty Ltd	Australia	100%	100%

Note 23. Events after the reporting period

As announced on 8 July 2025, 27,360,500 Options expired during the June 2025 quarter and on 1 July 2025, because the conditions have not been, or have become incapable of being, satisfied.

On 23 July 2025, the Company announced a fully underwritten non-renounceable Entitlement Offer to raise approximately \$1,774,357. On 27 August 2025 the Company advised that it has received applications under the Offer from eligible shareholders amounting to 423,479,439 Shares raising gross proceeds of \$423,479. On 28 August 2025, the Company issued a total of 529,349,257 shares, being the 423,479,439 shares applied for and accepted by eligible shareholders under the Offer, plus 105,869,818 free attaching shares. On 4 September 2025, the Company issued a total of 1,688,597,451 fully paid ordinary shares comprising of 1,350,877,963 shortfall Shares and 337,719,488 shortfall free attaching Shares raising \$1,350,878 from the Underwriter (and sub-underwriters).

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Note 24. Reconciliation of loss after income tax to net cash used in operating activities

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Loss after income tax expense for the year	(3,013,303)	(3,539,150)
Adjustments for:		
Depreciation and amortisation	49,301	46,997
Impairment of intangibles	303,750	-
Share based payments	-	163,291
Change in operating assets and liabilities:		
Decrease in trade and other receivable	515,984	1,500,293
Decrease in prepayments	54,737	15,377
Increase/(decrease) in trade and other payables	557,891	(57,866)
(Decrease)/increase in other provisions	(242,542)	55,121
Net cash used in operating activities	<u>(1,774,182)</u>	<u>(1,815,937)</u>

Note 25. Loss per share

	Consolidated	
	30 June 2025	30 June 2024
	\$	\$
Loss after income tax attributable to the Owners of Patrys Limited	<u>(3,013,303)</u>	<u>(3,539,150)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	2,066,733,011	2,055,750,236
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>2,066,733,011</u>	<u>2,055,750,236</u>
	Cents	Cents
Basic losses per share	(0.1458)	(0.1722)
Diluted losses per share	(0.1458)	(0.1722)

As at 30 June 2025, the Group had 37,889,950 (2024: 101,500,000) quoted and unquoted options, which are excluded from the calculation of basic and diluted earnings per share. These equity instruments are considered to be anti-dilutive, as their inclusion would not decrease earnings per share nor increase the loss per share, from continuing operations.

Note 25. Loss per share (continued)

Accounting policy for earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the loss attributable to the Owners of Patrys Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income-tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Note 26. Share based payments

The following share-based payment arrangements were in existence during the current and/or prior reporting period:

Employee equity

The Company issues equity to directors, employees and key consultants of the Group, under either the Loan Share Plan (LSP) or the Executive Share Option Plan (ESOP). Under the plans, participants are issued with equity to foster an ownership culture within the Company to motivate them to achieve performance targets of the Group. Participation in the plans is at the Board's discretion and no individual has a contractual right to participate in the plans or to receive any guaranteed benefits.

Executive Share Option Plan (ESOP)

Options are granted under the ESOP. Under the ESOP each option granted converts into one ordinary share of Patrys Limited. Options are granted under the plan for no consideration and carry no dividend or voting rights. Options may be exercised at any time from the date of vesting to the date of their expiry. The options are typically issued in two or three equal tranches which vest over a three-year period, each tranche having varied expiry dates after vesting date. The exercise period in relation to an option, means the period in which the option may be exercised, and is specified by the Board. If a participant ceases to be appointed as a director or employed by any member of the Group (other than due to his/her death) then, generally, options that have vested at the date of cessation of appointment/employment will lapse if not exercised within six months of the cessation date unless an extension is granted by the Board. In the case of death of the participant then the exercise period is extended to twelve months. All unvested options will generally lapse on cessation.

The valuations of shares issued under the LSP and options issued under the ESOP are determined by using an industry standard option pricing model taking into account the terms and conditions upon which the instruments were issued.

The Board aims to ensure that the aggregate number of shares or options which may be issued pursuant to the LSP and ESOP shall not at any time exceed 5% of the total number of issued shares of the company (not including any issues made under the ESOP to Directors of the company). All issues of shares or options under the plans are subject to approval by the Nomination & Remuneration Committee.

Note 26. Share based payments (continued)

30 June 2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/09/2019	31/08/2024	\$0.0290	1,500,000	-	-	(1,500,000)	-
01/10/2019	01/10/2024	\$0.0350	4,000,000	-	-	(4,000,000)	-
08/05/2020	08/05/2025	\$0.0240	250,000	-	-	(250,000)	-
15/03/2025	15/03/2025	\$0.0220	2,750,000	-	-	(2,750,000)	-
15/12/2020	15/12/2024	\$0.0270	22,000,000	-	-	(22,000,000)	-
05/11/2021	30/09/2025	\$0.0590	25,000,000	-	-	-	25,000,000
17/11/2021	30/09/2025	\$0.0590	16,250,000	-	-	(7,000,000)	9,250,000
19/11/2021	30/09/2025	\$0.0590	250,000	-	-	-	250,000
19/11/2021	15/03/2026	\$0.0590	2,500,000	-	-	-	2,500,000
16/11/2022	14/11/2026	\$0.0450	8,000,000	-	-	(6,000,000)	2,000,000
11/05/2023	10/04/2026	\$0.0450	18,500,000	-	-	(18,500,000)	-
11/05/2023	30/09/2026	\$0.0450	500,000	-	-	-	500,000
			101,500,000	-	-	(62,000,000)	39,500,000

Weighted average exercise price \$0.0458 \$0.0000 \$0.0000 \$0.0380 \$0.0581

30 June 2024

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
22/11/2018	22/11/2023	\$0.0350	28,000,000	-	-	(28,000,000)	-
15/03/2019	15/03/2024	\$0.0290	3,000,000	-	-	(3,000,000)	-
12/09/2019	31/08/2024	\$0.0290	1,500,000	-	-	-	1,500,000
01/10/2019	01/10/2024	\$0.0350	4,000,000	-	-	-	4,000,000
15/03/2020	15/03/2025	\$0.0220	2,750,000	-	-	-	2,750,000
08/05/2020	05/05/2025	\$0.0170	250,000	-	-	-	250,000
08/05/2020	05/08/2023	\$0.0240	7,500,000	-	(30,001)	(7,469,999)	-
21/12/2020	05/08/2023	\$0.0240	1,250,000	-	(148,940)	(1,101,060)	-
15/12/2020	15/12/2023	\$0.0400	8,300,000	-	-	(8,300,000)	-
15/12/2020	15/12/2024	\$0.0270	22,000,000	-	-	-	22,000,000
05/11/2021	30/09/2025	\$0.0590	25,000,000	-	-	-	25,000,000
17/11/2021	30/09/2025	\$0.0590	16,250,000	-	-	-	16,250,000
19/11/2021	30/09/2025	\$0.0590	250,000	-	-	-	250,000
19/11/2021	15/03/2026	\$0.0590	2,500,000	-	-	-	2,500,000
16/11/2022	14/11/2026	\$0.0450	8,000,000	-	-	-	8,000,000
11/05/2023	10/04/2026	\$0.0450	18,500,000	-	-	-	18,500,000
11/05/2023	30/09/2026	\$0.0450	500,000	-	-	-	500,000
			149,550,000	-	(178,941)	(47,871,059)	101,500,000

Weighted average exercise price \$0.0419 \$0.0000 \$0.0240 \$0.0335 \$0.0458

Set out below are the options exercisable at the end of the financial year:

Note 26. Share based payments (continued)

Grant date	Expiry date	30 June 2025 Number	30 June 2024 Number
22/11/2018	22/11/2023	-	19,000,000
15/03/2019	15/03/2024	-	3,000,000
12/09/2019	31/08/2024	-	1,500,000
01/10/2019	01/10/2024	-	3,000,000
15/03/2020	15/03/2025	-	2,750,000
08/05/2020	05/05/2025	-	250,000
05/05/2020	05/08/2023	-	7,500,000
21/12/2020	05/08/2023	-	1,250,000
15/12/2020	15/12/2023	-	8,300,000
15/12/2020	18/12/2024	-	21,400,000
17/11/2021	30/09/2025	-	500,000
19/11/2021	30/09/2025	-	2,500,000
16/11/2022	14/11/2026	2,000,000	2,000,000
11/05/2023	10/04/2026	4,625,000	4,625,000
11/05/2023	30/09/2026	-	500,000
		<u>6,625,000</u>	<u>78,075,000</u>

The weighted average remaining contractual life of options outstanding at the end of the financial year was 0.36 years (2024: 1.55 years).

Accounting policy for share-based payments

Equity-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

Note 26. Share based payments (continued)

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest %	Tax residency
Patrys Limited	Body corporate	Australia	-	Australia
Nucleus Therapeutics Pty Ltd	Body corporate	Australia	100.00%	Australia
Payload Therapeutics Pty Ltd	Body corporate	Australia	100.00%	Australia
Transmab Pty Ltd	Body corporate	Australia	100.00%	Australia

Basis of preparation

This Consolidated entity disclosure statement (CEDS) has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the Consolidated Entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.

Determination of tax residency

Section 295 (3A)(vi) of the Corporation Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are different interpretations that could be adopted, and which could give rise to a different conclusion on residency.

In determining tax residency, the Group has applied the following interpretations:

Australian tax residency

The Group has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5.

In the Directors' opinion:

- the attached financial statements and notes comply with the Australian Accounting Standards, the *Corporations Act 2001* and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the *Corporations Act 2001*.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the *Corporations Act 2001*.

On behalf of the Directors



Peter Christie
Chair

5 September 2025

INDEPENDENT AUDITOR'S REPORT

To the members of Patrys Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Patrys Limited (the Company) and its subsidiaries (the Group), which comprises the statement of financial position as at 30 June 2025, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

- (i) Giving a true and fair view of the Group's financial position as at 30 June 2025 and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to Note 2 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our opinion is not modified in respect of this matter.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the *Material uncertainty related to going concern* section, we have determined the matters described below to be the key audit matters to be communicated in our report.

Revenue Recognition, including the Existence and Accuracy of Research and Development (R&D) Tax Incentive

Key audit matter	How the matter was addressed in our audit
<p>Patrys Limited has recognised revenue being the R&D tax incentive of \$807,271 for the year ended 30 June 2025 and the corresponding receivable on the statement of financial position as at 30 June 2025.</p> <p>This is a key audit matter because the calculation of the R&D tax incentive is complex and requires a level of judgement as to the amount of eligible expenditure that can be claimed, methodology adopted and the appropriate rate to be applied.</p>	<p>Our procedures included the following, amongst others:</p> <ul style="list-style-type: none"> Assessing the accounting policy on the recognition of the R&D tax incentive with prior year to determine if there have been any changes and against the requirements of the Australian Accounting Standards. Performing testing on a sample basis of the R&D expenditure incurred during the financial year to underlying supporting documentation in order to verify the existence of the expenditure claimed. Obtaining the R&D workings as prepared by management's experts and engaging our Indirect Tax experts to review the appropriateness of the expenditure claimed, the methodology adopted and the tax rate applied. Assessing the appropriateness of the disclosures included in the financial report with reference to the requirements of the Australian Accounting Standards.

Impairment assessment of the Intellectual Property (IP)

Key audit matter	How the matter was addressed in our audit
<p>Patrys Limited holds an IP being a fixed life intangible asset relating to its deoxymab antibody technologies, PAT-DX1 and PAT-DX3.</p> <p>Fixed life intangible assets are required to be assessed for impairment when there are indicators of impairment as required by Australian Accounting Standards.</p> <p>This is a key audit matter because the impairment assessment process for the IP requires significant judgement based on the latest developments on the deoxymab antibody technologies.</p>	<p>Our procedures included the following, amongst others:</p> <ul style="list-style-type: none"> Assessing and challenging management's assessment for indicators of impairment in relation to the IP. Enquiring and challenging the board's view on the recoverability of the IP. Verifying for appropriateness of the accounting journals made in recognition of the impairment of the IP. Assessing for the appropriateness and adequacy of the disclosures included in the financial report on the impairment of the IP with reference to the requirements of the Australian Accounting Standards.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2025, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf

This description forms part of our auditor's report.



Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 9 to 15 of the directors' report for the year ended 30 June 2025.

In our opinion, the Remuneration Report of Patrys Limited, for the year ended 30 June 2025, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO Audit Pty Ltd

BDO


Wai Aw
Director

Melbourne, 5 September 2025

The shareholder information set out below was applicable as at 4 September 2025.

Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

	Number of holders of ordinary shares	Number of ordinary shares	% of ordinary shares	Number of holders of unlisted options	Number of unlisted options	% of unlisted options
1 - 1,000	134	11,515	0.00	-	-	-
1,001 - 5,000	53	213,205	0.00	-	-	-
5,001 - 10,000	115	988,620	0.02	-	-	-
10,001 - 100,000	1,361	63,629,791	1.39	-	-	-
100,001 - and over	1,453	4,518,913,447	98.59	6	37,889,950	100.00
	3,116	4,583,756,578	100.00	6	37,889,950	100.00
Holding less than a marketable parcel	2,454	245,802,770	5.36	-	-	-

Twenty largest quoted equity security holders

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares % of total Number held	Shares issued
MR ANTON UVAROV	250,000,000	5.45
MR MLADEN MARUSIC	133,828,078	2.92
WARRAGOON INVESTMENTS PTY LTD	130,937,500	2.86
HEVEL PTY LTD <COLOURFUL A/C>	121,699,223	2.66
CITICORP NOMINEES PTY LIMITED	113,152,317	2.47
COSANN PTY LTD	106,356,036	2.32
MR DENNIS BRIAN JONES + MRS JENNIFER ANNE JONES <JONES SUPER FUND A/C>	100,000,000	2.18
STORK HOLDINGS 2010 LTD	98,773,814	2.15
DR DAX MARCUS CALDER	89,000,000	1.94
MR ROBERT PHILIP GRANT	87,510,643	1.91
RATDOG PTY LTD	87,500,000	1.91
BT GLOBAL HOLDINGS PTY LTD <BT UNIT A/C>	81,387,485	1.78
MR PAUL GREGORY BROWN + MRS JESSICA ORIWIA BROWN <BROWN SUPER FUND A/C>	75,001,401	1.64
ASCENSION GROWTH (WA) FUND PTY LTD	73,437,500	1.60
MR PETER DARREN RUSSELL	73,125,000	1.60
DAX CALDER PTY LTD	65,000,000	1.42
TOWNS CORPORATION PTY LTD <PAE FAMILY A/C>	61,447,812	1.34
BG DEVELOPMENT FUND PTY LTD <BG INVESTMENT A/C>	50,000,000	1.09
SABRE POWER SYSTEMS PTY LTD	46,146,250	1.01
WENDAKE PTY LTD <L'HEUREUX A/C>	43,125,701	0.94
	1,887,428,760	41.18

Unquoted equity securities

	Number on issue	Number of holders
Options over ordinary shares issued	37,889,950	6

Substantial holders

Substantial holders in the Company, as disclosed in substantial holding notices given to the Company, are set out below:

	Ordinary shares Number held
Mr Anton Uvarov	250,000,000
Dr Dax Marcus Calder*	120,117,634

*Indicative relevant interest in shares based on number of voting securities recorded as at the date of their last substantial shareholder notice lodged with ASX.

Voting rights

The voting rights attached to ordinary shares are set out below:

Ordinary shares

All issued shares carry voting rights on a one-for-one basis.

Unquoted Options

There are no voting rights attached to the unquoted options.

There are no other classes of equity securities.

Corporate Governance Statement

Refer to the Company's Corporate Governance statement at: <https://patrys.com/investors/#corporate-governance>